SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 60.86+11.2%Jan 22 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: quidditch who wrote (10591)2/24/2004 12:13:59 PM
From: Biomaven  Read Replies (1) of 52153
 
<MSHL, NVGN>

quid,

No idea - there's been no change in the fundamentals that I have seen. But there's been weakness in a lot of cancer-oriented stocks the last week or so. The only overall negatives I know of are the FDA commissioner and mutterings about Medicare not wanting to pay for off-label uses of expensive drugs.

I have a small position in both stocks - I might add if the weakness continues. Phenoxodiol is still very early of course.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News